Post
of 1,418
If institutional investors put their MONey where their month is, funding 3CL Pharma shouldn't be problem. We know it will be at a higher valuation than Todos's market cap. That should have an immediate impact to Todos sp once people put 2 and 2 together.
Gerald Commissiong@G_Commish 1h
We believe we do. From the institutional investors we have spoken to it’s very clear. Tollovir for Long COVID. They view this as much bigger than hospitalized COVID
Gerald Commissiong@G_Commish 48m
I’m aware and agree. But most of the money from institutions wants to see Long COVID funded. The upside is that I think given that opportunity we should be able to raise enough for both Tollovir programs. The Tollovid data gives great confidence Tollovir will likely be a success
Gerald Commissiong@G_Commish 1h
We believe we do. From the institutional investors we have spoken to it’s very clear. Tollovir for Long COVID. They view this as much bigger than hospitalized COVID
Gerald Commissiong@G_Commish 48m
I’m aware and agree. But most of the money from institutions wants to see Long COVID funded. The upside is that I think given that opportunity we should be able to raise enough for both Tollovir programs. The Tollovid data gives great confidence Tollovir will likely be a success
1